<DOC>
	<DOCNO>NCT00000956</DOCNO>
	<brief_summary>To evaluate safety immune response 640 1280 mcg HIV-1 recombinant envelope glycoprotein gp160 . To evaluate duration antibody response relationship dose frequency inoculation . Evaluation previous patient receive dos 40 80 mcg gp160 vaccine indicate , although serum anti-gp160 antibody response detect , level duration response limit . A preliminary observation suggest weak functional antibody response may develop follow 18 month booster 40 80 mcg ; therefore , dose gp160 vaccine potentially great immunogenicity particular interest .</brief_summary>
	<brief_title>A Phase I Multicenter Trial Evaluate Safety Immunogenicity HIV-1 Recombinant Envelope Glycoprotein gp160</brief_title>
	<detailed_description>Evaluation previous patient receive dos 40 80 mcg gp160 vaccine indicate , although serum anti-gp160 antibody response detect , level duration response limit . A preliminary observation suggest weak functional antibody response may develop follow 18 month booster 40 80 mcg ; therefore , dose gp160 vaccine potentially great immunogenicity particular interest . In initial phase study , 20 healthy volunteer receive 640 mcg gp160 vaccine 5 healthy volunteer receive alum placebo . At least 30 day later , 20 additional volunteer receive 1280 mcg gp160 vaccine 5 volunteer receive placebo . Injections give day 0 , 30 , 180 , 365 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Inclusion Criteria Patients must : Normal history physical exam . Negative HIV infection ELISA Western blot ( i.e. , reactivity gp160 , gp120 , gp41 , p24 ) . T4 count &gt; = 800 cells/mm3 . Normal chest xray urinalysis . Negative hepatitis B surface antigen . Negative HIV p24 antigen test . Normal skin reactivity Merieux test . Exclusion Criteria Coexisting Condition : Subjects follow symptoms condition exclude : Positive PPD . Syphilis , gonorrhea , sexually transmit disease ( include chlamydia pelvic inflammatory disease ) . Subjects follow prior condition exclude : History immunodeficiency , chronic illness , use immunosuppressive medication . Syphilis , gonorrhea , sexually transmit disease ( include chlamydia pelvic inflammatory disease ) past 6 month . Prior Treatment : Excluded : Prior blood transfusion cryoprecipitates within past 6 month . Identifiable highrisk behavior HIV infection ( determined prescreening question design identify risk factor HIV infection ) , include : Any history IV drug use . Syphilis , gonorrhea , sexually transmit disease ( include chlamydia pelvic inflammatory disease ) past 6 month . More two sexual partner , sexual contact highrisk partner , past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Vaccinia Virus</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV Envelope Protein gp160</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>